Capstone Therapeutics (OTCMKTS:CAPS) Stock Price, News, Analysis & History

$0.05 0.00 (0.00 %)
(As of 03/23/2018 04:00 PM ET)
Previous Close$0.05
Today's Range$0.05 - $0.05
52-Week Range$0.04 - $0.09
Volume5 shs
Average Volume15,398 shs
Market Capitalization$2.72 million
P/E RatioN/A
Dividend YieldN/A

About Capstone Therapeutics (OTCMKTS:CAPS)

Capstone Therapeutics Corp. is a biotechnology company. The Company is engaged in developing a pipeline of peptides and other molecules aimed at helping patients with under-served medical conditions. The Company entered into a joint venture, LipimetiX Development, Inc., to develop Apo E mimetic peptide molecule AEM-28 and its analogs for the treatment for Homozygous Familial Hypercholesterolemia, Acute Hypertriglyceridemic Pancreatitis, diabetic dyslipidemia and other hyperlipidemic indications. Apolipoprotein E is a 299 amino acid protein that plays a role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14, a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan receptors (Syndecan-1) in the liver.

Receive CAPS News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry DRUGS


Debt-to-Equity Ratio-2.57%
Current Ratio7.21%
Quick Ratio7.21%


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-2.50


Trailing EPSN/A
Net Income$-1,750,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-135.17%


Outstanding Shares54,380,000

Capstone Therapeutics (OTCMKTS:CAPS) Frequently Asked Questions

What is Capstone Therapeutics' stock symbol?

Capstone Therapeutics trades on the OTCMKTS under the ticker symbol "CAPS."

How were Capstone Therapeutics' earnings last quarter?

Capstone Therapeutics Corp (OTCMKTS:CAPS) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. View Capstone Therapeutics' Earnings History.

When will Capstone Therapeutics make its next earnings announcement?

Capstone Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Capstone Therapeutics.

Who are some of Capstone Therapeutics' key competitors?

Who are Capstone Therapeutics' key executives?

Capstone Therapeutics' management team includes the folowing people:

  • John M. Holliman III, Executive Chairman of the Board, Principal Executive Officer (Age 61)
  • Leslie M. Taeger, Chief Financial Officer, Senior Vice President, Principal Financial and Accounting Officer (Age 65)
  • Randolph C. Steer MD. Ph.D., Consultant (Age 67)
  • Fredric J. Feldman Ph.D., Director (Age 76)
  • Matthew E. Lipman, Director
  • Michael E. Toporek, Director
  • Elwood D. Howse Jr., Independent Director (Age 75)

Has Capstone Therapeutics been receiving favorable news coverage?

News coverage about CAPS stock has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capstone Therapeutics earned a coverage optimism score of 0.08 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Capstone Therapeutics?

Shares of CAPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capstone Therapeutics' stock price today?

One share of CAPS stock can currently be purchased for approximately $0.05.

How big of a company is Capstone Therapeutics?

Capstone Therapeutics has a market capitalization of $2.72 million. Capstone Therapeutics employs 2 workers across the globe.

How can I contact Capstone Therapeutics?

Capstone Therapeutics' mailing address is 1275 W. Washington Street Suite 104, Tempe AZ, 85281. The biotechnology company can be reached via phone at 602-286-5520 or via email at [email protected]

MarketBeat Community Rating for Capstone Therapeutics (CAPS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Capstone Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Capstone Therapeutics (OTCMKTS:CAPS) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Capstone Therapeutics (OTCMKTS:CAPS) Earnings History and Estimates Chart

Earnings by Quarter for Capstone Therapeutics (OTCMKTS:CAPS)

Capstone Therapeutics (OTCMKTS CAPS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.01)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.01)ViewN/AView Earnings Details
7/29/2016Q3 2016($0.01)ViewN/AView Earnings Details
5/13/2016Q1 2016($0.01)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.02)ViewN/AView Earnings Details
11/9/2015Q3 2015$0.01ViewN/AView Earnings Details
8/13/2015Q2($0.02)ViewListenView Earnings Details
5/14/2015Q1 2015$0.02ViewN/AView Earnings Details
3/16/2015Q4 2014$0.01ViewN/AView Earnings Details
11/13/2014Q3 2014($0.03)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.03)ViewN/AView Earnings Details
3/27/2014Q4 2013($0.02)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.03)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.02)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.02)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.03)ViewN/AView Earnings Details
11/8/2012Q3 2012$0.02ViewN/AView Earnings Details
5/10/2012Q1 2012($0.02)ViewN/AView Earnings Details
3/21/2012Q4 2011($0.07)ViewN/AView Earnings Details
11/10/2011Q3 2011$0.04ViewN/AView Earnings Details
8/12/2011Q2 2011($0.05)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.08)ViewN/AView Earnings Details
11/10/2010Q3 2010$0.06ViewN/AView Earnings Details
8/9/2010Q2 2010$0.07ViewN/AView Earnings Details
11/9/2009Q3 2009$0.08ViewN/AView Earnings Details
8/12/2009Q2 2009($0.08)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.10)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.08)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.07)ViewN/AView Earnings Details
5/7/2008Q1 2008$0.06ViewN/AView Earnings Details
3/5/2008Q4 2007($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Capstone Therapeutics (OTCMKTS:CAPS) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Capstone Therapeutics (OTCMKTS:CAPS)

No dividend announcements for this company have been tracked by

Insider Trades

Capstone Therapeutics (OTCMKTS CAPS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.40%
Insider Trades by Quarter for Capstone Therapeutics (OTCMKTS:CAPS)

Capstone Therapeutics (OTCMKTS CAPS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/5/2017Lloyd I Miller IIIMajor ShareholderSell100,000$0.06$6,000.00View SEC Filing  
7/14/2017Value Fund L P BiotechnologyInsiderSell4,341,586$0.06$260,495.16View SEC Filing  
1/4/2017Leslie M TaegerCFOBuy50,000$0.07$3,500.0094,574View SEC Filing  
12/16/2016Lloyd I. Miller IIIMajor ShareholderSell38,967$0.04$1,558.68View SEC Filing  
12/15/2016Lloyd I Miller IIIMajor ShareholderSell20,000$0.04$800.0038,967View SEC Filing  
8/12/2016Lloyd I Miller IIIMajor ShareholderSell16,000$0.06$960.0058,967View SEC Filing  
8/1/2016Lloyd I Miller IIIMajor ShareholderSell80,000$0.06$4,800.0058,967View SEC Filing  
6/8/2016Lloyd I Miller IIIMajor ShareholderSell14,000$0.08$1,120.0058,967View SEC Filing  
12/6/2013John M Holliman IIIChairmanBuy25,000$0.26$6,500.00View SEC Filing  
8/7/2013Lloyd I Miller IIIMajor ShareholderBuy87,500$0.23$20,125.00View SEC Filing  
7/30/2013Lloyd I Miller IIIMajor ShareholderBuy1,139,000$0.20$227,800.00View SEC Filing  
6/10/2013Lloyd I Miller IIIMajor ShareholderBuy300,000$0.18$54,000.00View SEC Filing  
4/8/2013Fredric J FeldmanDirectorBuy25,000$0.21$5,250.00View SEC Filing  
12/17/2012Lloyd I Miller IIIMajor ShareholderBuy175,000$0.16$28,000.00View SEC Filing  
12/6/2012Lloyd I Miller IIIMajor ShareholderBuy19,750$0.16$3,160.00View SEC Filing  
10/19/2012John M Holliman IIIChairmanBuy150,000$0.14$21,000.00View SEC Filing  
9/19/2012Lloyd I Miller IIIMajor ShareholderBuy261,183$0.16$41,789.28View SEC Filing  
8/28/2012Lloyd I Miller IIIMajor ShareholderBuy938,064$0.16$150,090.24View SEC Filing  
(Data available from 1/1/2013 forward)


Capstone Therapeutics (OTCMKTS CAPS) News Headlines


SEC Filings

Capstone Therapeutics (OTCMKTS:CAPS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Capstone Therapeutics (OTCMKTS:CAPS) Income Statement, Balance Sheet and Cash Flow Statement


Capstone Therapeutics (OTCMKTS CAPS) Stock Chart for Saturday, March, 24, 2018

Loading chart…

This page was last updated on 3/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.